Join
Live feed
·
PRReleasevia Quantisnow
Protara Therapeutics Inc. logo

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

ByQuantisnow·Wall Street's wire, on your screen.
TARA· Protara Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TARA (Protara Therapeutics Inc.) and more on Quantisnow.